Magazine Article | January 2, 2019

The Unique Challenges Facing Cannabis-based Pharma

Source: Life Science Leader

By Camille Mojica Rey, Contributing Writer
Follow Me On Twitter @CamilleReyATX

In June 2018, the FDA approved the first-ever pharmaceutical derived from the cannabis plant, Epidiolex (cannabidiol, CBD). GW Pharmaceuticals’ lead therapeutic reduces the frequency of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. The oral solution is approved for use in patients 2 years of age and older.

In the U.S., marijuana is a Schedule 1 drug, along with heroin and LSD. Three months after its approval, as required by law, Epidiolex was rescheduled to a Schedule 5 drug, the lowest restriction classification, due to its low potential for abuse. The approval was seen as a breakthrough by the leaders of the growing number of pharmaceutical companies working to bring cannabis-derived pharmaceuticals to market. That’s because these companies face a unique tangle of legal, scientific, and societal challenges — and they believe GW is paving the way for them to follow.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: